Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Identification of vitamin D receptor as a target of p63

Oncogene volume 25, pages 3745–3751 (2006)Cite this article

Abstract

p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63γ specifically upregulates vitamin D Receptor (VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63γ (R279H) and p14ARF, both act in a dominant negative manner to inhibit p63γ-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Banerjee P, Chatterjee M . (2003). Mol Cell Biochem 253: 247–254.

  • Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA . (2005). Cancer Res 65: 2314–2320.

  • Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T, van Beersum SE, Gorlin R et al. (2002). J Med Genet 39: 559–566.

  • Bikle DD . (1992). Endocr Rev 13: 765–784.

  • Bikle DD . (2004). J Nutr 134: 3472S–3478S.

  • Bikle DD, Oda Y, Xie Z . (2004). J Steroid Biochem Mol Biol 89-90: 355–360.

  • Bikle DD, Tu CL, Xie Z, Oda Y . (2003). J Cell Biochem 88: 290–295.

  • Blutt SE, Weigel NL . (1999). Proc Soc Exp Biol Med 221: 89–98.

  • Brunner HG, Hamel BC, Bokhoven Hv H . (2002a). Am J Med Genet 112: 284–290.

  • Brunner HG, Hamel BC, Van Bokhoven H . (2002b). J Med Genet 39: 377–381.

  • Calabro V, Mansueto G, Santoro R, Gentilella A, Pollice A, Ghioni P et al. (2004). Mol Cell Biol 24: 8529–8540.

  • Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP et al. (1999). Cell 99: 143–153.

  • Christakos S, Barletta F, Huening M, Dhawan P, Liu Y, Porta A et al. (2003). J Cell Biochem 88: 238–244.

  • Feldman D, Zhao XY, Krishnan AV . (2000). Endocrinology 141: 5–9.

  • Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H et al. (2005). EMBO J 24: 2458–2471.

  • Guzey M, Luo J, Getzenberg RH . (2004). J Cell Biochem 93: 271–285.

  • Honda R, Yasuda H . (1999). EMBO J 18: 22–27.

  • Hudson DL . (2004). Prostate Cancer Prostatic Dis 7: 188–194.

  • Kim S, Han J, Kim J, Park C . (2004). Cancer Res 64: 6900–6905.

  • Konety BR, Johnson CS, Trump DL, Getzenberg RH . (1999). Semin Urol Oncol 17: 77–84.

  • Koszewski NJ, Reinhardt TA, Horst RL . (1996). J Steroid Biochem Mol Biol 59: 377–388.

  • Lian JB, Stein GS . (2003). Curr Pharm Des 9: 2677–2685.

  • Lu J, Goldstein KM, Chen P, Huang S, Gelbert LM, Nagpal S . (2005). J Invest Dermatol 124: 778–785.

  • Miller GJ . (1998). Cancer Metastasis Rev 17: 353–360.

  • Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A . (1999). Nature 398: 708–713.

  • Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S et al. (1997). Mol Endocrinol 11: 1165–1179.

  • Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT . (1990). Proc Natl Acad Sci USA 87: 9995–9999.

  • Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I et al. (1998). Nat Med 4: 839–843.

  • Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, Kim MS et al. (2005). Mol Cell Biol 25: 6077–6089.

  • Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J et al. (2001). J Cell Biol 154: 369–387.

  • Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R et al. (2002). Cancer Cell 1: 369–379.

  • Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron de Fromentel C . (2005). Oncogene 24: 512–519.

  • Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. (1998). Cell 92: 713–723.

  • Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C et al. (2002a). J Biol Chem 277: 719–724.

  • Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C et al. (2002b). J Biol Chem 277: 719–724.

  • Sasaki Y, Naishiro Y, Oshima Y, Imai K, Nakamura Y, Tokino T . (2005). Oncogene 24: 5131–5136.

  • Senoo M, Matsumura Y, Habu S . (2002). Oncogene 21: 2455–2465.

  • Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K et al. (1999). Cancer Res 59: 2781–2786.

  • South AP, Ashton GH, Willoughby C, Ellis IH, Bleck O, Hamada T et al. (2002). Br J Dermatol 146: 216–220.

  • Spiesbach K, Tannapfel A, Mossner J, Engeland K . (2005). Int J Cancer 114: 555–562.

  • van Bokhoven H, McKeon F . (2002). Trends Mol Med 8: 133–139.

  • Wagner EF, Karseny G . (2001). Curr Opin Genet Dev 11: 527–532.

  • Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA . (2003). Mol Cell Biol 23: 2264–2276.

  • Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC et al. (2003). Cancer Res 63: 2351–2357.

  • Xie Z, Komuves L, Yu QC, Elalieh H, Ng DC, Leary C et al. (2002). J Invest Dermatol 118: 11–16.

  • Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998). Mol Cell 2: 305–316.

  • Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. (1999). Nature 398: 714–718.

  • Zhang Y, Xiong Y . (1999). Mol Cell 3: 579–591.

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Dayton, OH, USA

    R Kommagani, T M Caserta & M P Kadakia

  2. Center for Genomics Research, Wright State University, Dayton, OH, USA

    T M Caserta & M P Kadakia

Authors
  1. R Kommagani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T M Caserta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M P Kadakia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M P Kadakia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kommagani, R., Caserta, T. & Kadakia, M. Identification of vitamin D receptor as a target of p63. Oncogene 25, 3745–3751 (2006). https://doi.org/10.1038/sj.onc.1209412

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209412

Keywords

This article is cited by

Search

Advanced search

Quick links